alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 676–700 of 881 studies in Cognitive tests and assessment (page 28 of 36) · 27,780 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Other subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 13,259 studies have no institution on record and are not counted here.

What “Cognitive tests and assessment” covers

Cognitive tests and assessment — Memory and thinking tests, screening tools and rating scales: how well they measure what they claim to.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Alzheimer's disease comorbidity in normal pressure hydrocephalus: prevalence and shunt response

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Journal of neurology, neurosurgery, and psychiatry 2000-06-01

The clinical impact of Alzheimer's disease pathology at biopsy was investigated in 56 cognitively impaired patients undergoing shunt surgery for idiopathic normal pressure hydrocephalus (NPH). 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The Clock Drawing Test for dementia of the Alzheimer's type: A comparison of three scoring methods in a memory disorders clinic

✓ Peer-reviewed alzhub usefulness score 42 out of 100. International journal of geriatric psychiatry 1997-06-01

Retrospective analysis of clock drawing performance using three published scoring methods (Shulman, Sunderland and Wolf-Klein). 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Evaluation of chewing ability and its relationship with activities of daily living, depression, cognitive status and food intake in the community-dwelling elderly

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Geriatrics & gerontology international 2012-12-21

The aim of this study was to assess chewing ability using color-changeable chewing gum and to show the association between chewing ability and geriatric functions, as well as dietary status in the community-dwelling elderly. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Psychiatric morbidity in terminally ill cancer patients. A prospective study

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Cancer 1996-09-01

In the study by Derogatis et al., which included patients with all stages of cancer, 47% of the patients met the DSM-III criteria for a psychiatric disorder, with adjustment disorders being the most common. 4 key findings →

Participants: 26 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Journal of geriatric psychiatry and neurology 1996-01-01

We conducted an open-label study designed to assess the effects of tacrine on behavioral changes in patients with Alzheimer's disease (AD). 4 key findings →

Design: open-label trial Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Instruments for screening for depression and dementia in a long-term care facility

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Journal of the American Geriatrics Society 1989-01-01

The high prevalence of mental disorders such as depression and dementia in institutionalized elderly patients warrants screening for psychiatric diagnosis in patients newly admitted to long-term care facilities. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Montreal Cognitive Assessment (MoCA): validation study for vascular dementia

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Journal of the International Neuropsychological Society : JINS 2012-06-08

The Montreal Cognitive Assessment (MoCA) is a brief instrument developed for the screening of milder forms of cognitive impairment, having surpassed the well-known limitations of the MMSE. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Accuracy of the Mini-Mental Status Examination as a screening test for dementia in a Swedish elderly population

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Acta neurologica Scandinavica 1993-04-01

The aim of this study was to determine the accuracy of the Mini-Mental Status Examination (MMSE) as a screening test for dementia in an elderly Swedish population. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Long-term estrogen replacement therapy in female patients with dementia of the Alzheimer type: 7 case reports

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Dementia (Basel, Switzerland) 1995-03-01

Seven female patients with mild to moderate dementia of the Alzheimer type (DAT) were treated with long-term, low-dose estrogen replacement therapy (ERT) over a period of 5-45 months. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Deciding on genetic testing for familial dementia: Perspectives of patients and families

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Alzheimer s & Dementia 2025-04-01

Of 138 (27%) eligible patients (46% female, age 61 ± 8 years, Mini-Mental State Examination [MMSE] 22 ± 6), 75 (54%) underwent genetic testing. 5 key findings →

Participants: 15 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Data-driven characterization of distinct cognitive subtypes in Parkinson’s disease dementia

✓ Peer-reviewed alzhub usefulness score 42 out of 100. npj Parkinson s Disease 2025-05-09

Individual cognitive profiles of patients with Parkinson's disease dementia (PDD) are highly heterogeneous, suggesting possible biological subtypes. 1 key finding →

Participants: 50 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Psychometric properties of International HIV Dementia Scale as screening tool for neurocognitive disorder among people living with HIV/AIDS

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Scientific Reports 2025-10-29

Multivariable linear regression analysis indicated that being married (β = 0.6, p-value = 0.02) and being a young adult (β = 0.52, p-value = 0.04) were significantly associated with better neurocognitive performance. 1 key finding →

Design: cross-sectional Participants: 59 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

CSF Acetylated Tau‐174 as a novel diagnostic and prognostic biomarker in Frontotemporal Dementia and Alzheimer’s Disease

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Alzheimer s & Dementia 2025-12-01

AcTau174 levels were elevated in all dementia groups compared to controls, with a stepwise increase from controls to MCI-AD (2.2-fold) to AD dementia (3.5-fold, Figure 1). 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Representing the Cognitive Impairment Continuum of Alzheimer's Disease and Lewy Body Dementia with a Novel Finer‐Scale Cortical Representation via Disease Embedding Tree

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Alzheimer s & Dementia 2025-12-01

The DET framework has achieved superior performance on the classification task across all the evaluation metrics compared to the traditional machine learning based methods, as demonstrated in Table 1. 4 key findings →

Participants: 106 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Intervening with everyday memory problems in dementia of Alzheimer type: an errorless learning approach

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Journal of clinical and experimental neuropsychology 2000-02-01

Dementia of Alzheimer Type (DAT) is increasingly detected at an earlier stage of the disorder, when interventions to assist with everyday memory difficulties might be most valuable. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed